This article is about a watershed moment in COVID-19 management. It is brought into focus by the TGA closing down the legal use of IVM for COVID-19, while Merck promotes an inadequately documented, potentially dangerous and less effective (but patented and very expensive) “lethal-mutant” anti-viral.
In ‘Real Life’ this 10-day Ivermectin Triple Therapy reported here, appears to be a very safe, effective and inexpensive early antiviral treatment for Covid-19. Further detail from the more than 30 doctors involved in treating this patient group, will be used for a formal peer-reviewed publication.
Five months after receiving the Pfizer vaccine, protection in Israel against mild-to-moderate disease was only 15 per cent. The unpredictable nature of new variants leads to an increasing realisation that a COVID-free community in Australia will not happen without draconian and continued lockdowns. There is an immediate need for early drug therapy to complement the vaccine program.
Oxford University is going to investigate the effectiveness of ivermectin as a COVID-19 treatment. Emeritus Professor Robert Clancy, an immunologist at the University of Newcastle, tells Paul Turton that he believes they’ll find the drug useful, and that it will become part of our coronavirus response.
